BPC-157 is a 15-residue pentadecapeptide at 1419.53 g/mol, while TB-500 is the 43-residue thymosin beta 4 sequence at 4963.4 g/mol
Cagrilintide's amylin mechanism (different pathway) How cagrilintide works: Amylin receptor agonist Long-acting weekly injection Investigational (not FDA approved) Different receptors than GIP/GLP-1 Amylin pathway effects: Very strong gastric emptying delay (stronger than GLP-1) Central appetite suppression (area postrema) Reduces meal frequency Suppresses glucagon Enhances satiety Cagrilintide monotherapy results: 10-12% average body weight loss Significant GI side effects (stronger gastric slowing) Currently in Phase 3 trials Not yet available pharmaceutically See our cagrilintide weight loss , cagrilintide dosing , and cagrilintide and semaglutide guides
PMID: 22005198
At a 159 195 h half-life it takes 4 5 weekly doses to reach steady state, where concentrations sit roughly 2 3 the first-dose peak
Peptide Therapy Explore physician-guided Wolverine Blend peptide therapy with BPC-157 and TB-500 for eligible patients interested in recovery support, tissue support, mobility, and wellness-focused care
At the 5:1:1 ratio, daily glow peptide administration provides approximately 330mcg BPC-157, falling squarely within established effective ranges